 |
市場調査レポート
商品コード
1452841
リポソーム化ドキソルビシンの世界市場：市場規模、シェア、成長分析 - 製品別、用途別、産業予測（2024～2031年）Global Liposomal Doxorubicin Market Size, Share, Growth Analysis, By Product(J7J (Doxil/Caelyx), Sun Pharma (Lipodox)), By Application(leukemia, bone sarcoma) - Industry Forecast 2024-2031 |
||||||
| リポソーム化ドキソルビシンの世界市場：市場規模、シェア、成長分析 - 製品別、用途別、産業予測（2024～2031年） |
|
出版日: 2024年03月10日
発行: SkyQuest
ページ情報: 英文 219 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
世界のリポソーム化ドキソルビシンの市場規模は、2022年に12億7,000万米ドル、2023年に13億5,000万米ドルに達し、2024～2031年の予測期間中にCAGR 6.1%で成長し、2031年には21億6,000万米ドルに成長すると予測されています。
リポソーム化ドキソルビシン市場は、主に肉腫の有病率の上昇によって著しい成長を遂げています。リポソーム化ドキソルビシンは、乳がん、卵巣がん、カポジ肉腫など、さまざまな悪性腫瘍の治療に利用されています。これは、閉じた脂質球体であるリポソームに封入された抗がん化学療法薬です。この世界市場の成長には、ヘルスケア施設の進歩、医療費の増加傾向、潜在的な治療法に関する患者の意識の高まり、必須医薬品のジェネリック医薬品の普及など、いくつかの要因が寄与しています。しかし、ジェネリック医薬品との競合激化や、新薬承認に関するFDAの厳しい要件により、市場拡大は課題に直面する可能性があります。さらに、代替薬に対する意識の高まりや、官民両部門の主なメーカーによる大規模な投資により、市場は収益性の高い開拓が見込まれます。リポソーム化ドキソルビシンの売上は、卵巣がんやAIDSに伴うカポジ肉腫に対するこれまでの全身治療が不十分であったため、大幅に増加すると予想されています。さらに、肝細胞がんの罹患率と生存率は上昇傾向にあり、リポソーム化ドキソルビシンの需要にさらに拍車をかけています。
目次
エグゼクティブサマリー
- 市場概要
- 運命の輪
調査手法
- 情報調達
- セカンダリ・プライマリデータソース
- 市場規模の推定
- 市場の前提条件・制限
親市場の分析
- 市場概要
- 市場規模
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
主な市場の考察
- 技術分析
- 価格分析
- サプライチェーン分析
- バリューチェーン分析
- 市場のエコシステム
- IP分析
- 貿易分析
- スタートアップ分析
- 原材料の分析
- イノベーションマトリクス
- パイプライン製品の分析
- マクロ経済指標
- 主な投資の分析
- 主な成功要因
- 競合の程度
市場力学と見通し
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 規制情勢
- ポーターの分析
- 将来の混乱についての特別な考察
世界のリポソーム化ドキソルビシン市場：製品別
- 市場概要
- J7J (Doxil/Caelyx)
- Sun Pharma (Lipodox)
- Teva (Myocet)
世界のリポソーム化ドキソルビシン市場：用途別
- 市場概要
- 白血病
- 骨肉腫
- 乳がん
- 胃がん
- 肝臓がん
- 腎臓がん
- 多発性骨髄腫
- 卵巣がん
- カポジ肉腫
- その他
世界のリポソーム化ドキソルビシン市場規模：地域別
- 市場概要
- 北米
- 米国
- カナダ
- 欧州
- ドイツ
- スペイン
- フランス
- 英国
- その他の欧州
- アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他のアジア太平洋
- ラテンアメリカ
- ブラジル
- その他のラテンアメリカ
- 中東・アフリカ
- GCC諸国
- 南アフリカ
- その他の中東・アフリカ
競合情勢
- 上位5社の比較
- 主要企業の市場ポジショニング（2021年）
- 主な市場企業が採用した戦略
- 主要成功戦略
- 市場における最近の活動
- 主要企業の市場シェア（2021年）
主要企業プロファイル
- Johnson & Johnson
- Sun Pharmaceutical Industries Ltd.
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Celsion Corporation
- Gilead Sciences, Inc.
- Eisai Co., Ltd.
- Ligand Pharmaceuticals
- Sandoz（a division of Novartis）
- Eagle Pharmaceuticals, Inc.
- Dr. Reddy's Laboratories Ltd.
- Pacira BioSciences, Inc.
- Formosa Laboratories, Inc.
- Intas Pharmaceuticals Ltd.
- Zydus Cadila
- TTY Biopharm
- Luye Pharma Group Ltd.
- CP Pharmaceuticals Ltd.
- Actavis（now part of Teva）
- Ipsen S.A.
Global Liposomal Doxorubicin Market size was valued at USD 1.27 billion in 2022 and is poised to grow from USD 1.35 billion in 2023 to USD 2.16 billion by 2031, growing at a CAGR of 6.1 % in the forecast period (2024- 2031).
The market for liposomal doxorubicin is experiencing notable growth, primarily driven by the escalating prevalence of sarcoma. Liposomal doxorubicin is utilized in the treatment of various malignant tumors, including breast cancer, ovarian cancer, Kaposi sarcoma, among others. It is an anti-cancer chemotherapy medication enclosed within liposomes, which are closed lipid spheres. Several factors contribute to the growth of this global market, including advancements in healthcare facilities, the upward trajectory of healthcare expenses, heightened patient awareness regarding potential therapies, and the proliferation of generic versions of essential medications. However, the market expansion may face challenges due to intensifying competition from generic medications and stringent FDA requirements for the approval of new drugs. Moreover, the market is poised to witness profitable development due to the increasing awareness of alternative medications and substantial investments made by key manufacturers in both public and private sectors. The sales of liposomal doxorubicin are anticipated to witness a significant upsurge owing to the inadequacy of prior systemic treatments for ovarian cancer and Kaposi's sarcoma associated with AIDS. Additionally, the incidence and survival rates of hepatocellular carcinoma are on the rise, further fueling the demand for liposomal doxorubicin.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Liposomal Doxorubicin Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Liposomal Doxorubicin Market Segmental Analysis
The Global Liposomal Doxorubicin Market is segmented on the basis of product, application, and region. By Product, the market is segmented into J7J (Doxil/Caelyx), Sun Pharma (Lipodox), and Teva (Myocet). By Applicatopn, the market is segmented into leukemia, bone sarcoma, breast cancer, gastric cancer, liver cancer, kidney cancer, multiple myeloma, ovarian cancer, Kaposi sarcoma, and others. By region, the market is segmented into North America, Latin America, Europe, Asia Pacific, and MEA.
Drivers of the Global Liposomal Doxorubicin Market
Liposomal doxorubicin is predominantly employed in the treatment of breast cancer, a disease that is witnessing a concerning surge in many countries. The growing innovation in formulations stands out as a key factor driving the increased adoption and usage of the drug for breast cancer treatment. These advancements contribute significantly to the expansion of the market. Moreover, several other factors are expected to further propel the market in the forthcoming years. These include the escalating demand for pharmaceuticals utilized in targeted therapy, the heightened utilization of chemotherapy treatments, and substantial investments by private enterprises in this particular application. Government support for the healthcare sector also emerges as a critical element in expanding the global reach of the market.
Restraints in the Global Liposomal Doxorubicin Market
Anticipated adverse effects of liposomal doxorubicin may potentially impede market expansion. These effects include an elevated risk of infection, dyspnea, pale complexion, bruises, nosebleeds, pre- and post-treatment weakness, red, painful, and peeling hands and feet, weight loss, diarrhea, and fatigue.
Market Trends of the Global Liposomal Doxorubicin Market
Breast cancer stands out as the most prevalent cancer treated with doxorubicin, although this medication is also employed in the treatment of various other malignancies. According to a report by the International Agency for Research on Cancer (IARC) in December 2020, approximately 1 in 4 cancer diagnoses in women worldwide are cases of breast cancer. As per a World Health Organization article dated April 2021, there were 2.3 million women diagnosed with breast cancer in 2020, resulting in 685,000 fatalities globally. Projections indicate that by 2020, a staggering 7.8 million women will have received a breast cancer diagnosis, solidifying its status as the most commonly diagnosed cancer globally. Additionally, according to the American Cancer Institute, doxorubicin is a chemotherapy medication prescribed for the treatment of advanced breast cancer.
Table of Contents
Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Global Liposomal Doxorubicin Market by Product
- Market Overview
- J7J (Doxil/Caelyx)
- Sun Pharma (Lipodox)
- and Teva (Myocet)
Global Liposomal Doxorubicin Market by Application
- Market Overview
- leukemia
- bone sarcoma
- breast cancer
- gastric cancer
- liver cancer
- kidney cancer
- multiple myeloma
- ovarian cancer
- Kaposi sarcoma
- and others
Global Liposomal Doxorubicin Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Celsion Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Gilead Sciences, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eisai Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ligand Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sandoz (a division of Novartis)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eagle Pharmaceuticals, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dr. Reddy's Laboratories Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pacira BioSciences, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Formosa Laboratories, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Intas Pharmaceuticals Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Zydus Cadila
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- TTY Biopharm
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Luye Pharma Group Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- CP Pharmaceuticals Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Actavis (now part of Teva)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ipsen S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
